A team of scientists from the USA recently developed a recombinant “Angiotensin converting enzyme 2 (ACE2) Triple Decoy” that can trap SARS-CoV-2 and prevent its propagation inside the host cell.
Novel CRISPR-based gene editor developed to correct mutations that cause genetic disorders
A team of researchers from the Agency for Science, Technology and Research s (A STAR) Genome Institute of Singapore (GIS) have developed a CRISPR-based gene editor, C-to-G Base Editor (CGBE), to correct mutations that cause genetic disorders. Their research was published in
Nature Communications on 2 March 2021.
One in seventeen people in the world suffers from some type of genetic disorder. Chances are, you or someone you know - a relative, friend, or colleague - is one of approximately 450 million people affected worldwide. Mutations responsible for these disorders can be caused by multiple mutagens - from sunlight to spontaneous errors in your cells. The most common mutation by far is the single-based substitution, in which a single-base in the DNA (such as G) is replaced by another base (such as C). Countless cystic fibrosis patients worldwide have C instead of G, leading to defective p
Study examines m6A regulators and m6A-related genes through integrated bioinformatic analysis
Announcing a new article publication for
BIO Integration journal. In this article the authors Jingdun Xie, Zhenhua Qi, Xiaolin Luo, Fang Yan, Wei Xing, Weian Zeng, Dongtai Chen and Qiang Li; from Sun Yat-sen University, Guangzhou, Guangdong, China discuss integration analysis of m6A regulators and m6A-related genes in hepatocellular carcinoma (HCC).
N6-Methyladenosine (m6A) RNA methylation of eukaryotic mRNA is involved in the progression of various tumors. This study comprehensively analyzed m6A regulators and m6A-related genes through an integrated bioinformatic analysis, including expression, clustering, protein-protein interaction, and prognosis, thus providing novel insights into the roles of m6A regulators and m6A-related genes in HCC.
Novel method can improve the detection of circulating tumor cells
Non-Small Cell Lung Cancer (NSCLC) is the most prevalent form of lung cancer, accounting for more than 80 percent of all lung cancer cases. Despite the aggressive nature of NSCLC, circulating tumor cells that lead to metastases often go undetected in the blood compared to breast, prostate, colorectal, and other cancers.
Now, scientists have developed a novel method to better detect the circulating tumor cells (CTCs) that are a telltale sign of metastases. The research was published in the journal
Proceedings of the National Academy of Sciences (
PNAS).
ISB and a collaborative team of researchers looked at hexokinase-2, or HK2, a key enzyme in glucose metabolism. A set of previous reports from our collaborator Dr. Herschman (co-author of the paper) and others revealed that cancer cells often rely on HK2 to elevate glucose metabolism to fuel their uncontrolled growth, making this enzyme a desirable target for test
Viruses evolve under increased pressure, and new research from The Rockefeller University and University of Massachusetts Medical School in the U.S. suggests our antibodies can as well.